Pacific Biosciences of California, Inc. (PACB)

Market Cap	453.25M
Revenue (ttm)	154.01M
Net Income (ttm)	-308.65M
Shares Out	294.32M
EPS (ttm)	-1.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,042,470
Open	1.690
Previous Close	1.640
Day's Range	1.530 - 1.690
52-Week Range	1.160 - 6.090
Beta	1.92
Analysts	Buy
Price Target	2.79 (+81.17%)
Earnings Date	Feb 13, 2025

About PACB

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified D...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 27, 2010
• Employees: 796
• Stock Exchange: NASDAQ
• Ticker Symbol: PACB
• Website: https://www.pacb.com

Financial Performance

In 2024, PACB's revenue was $154.01 million, a decrease of -23.19% compared to the previous year's $200.52 million. Losses were -$308.65 million, 0.62% more than in 2023.

Analyst Forecast

According to 13 analysts, the average rating for PACB stock is "Buy." The 12-month stock price forecast is $2.79, which is an increase of 81.17% from the latest price.

Price Target

$2.79

(81.17% upside)

Analyst Consensus: Buy